Volume 26, Number 7—July 2020
Research
Severe Acute Respiratory Syndrome Coronavirus 2−Specific Antibody Responses in Coronavirus Disease Patients
Table 2
Virus type | Virus | Nucleocapsid | S | S1 | S2 | S1A | RBD |
---|---|---|---|---|---|---|---|
Betacoronavirus |
SARS-CoV | 90 | 77 | 66 | 90 | 52 | 73 |
MERS-CoV | 49 | 33 | 24 | 43 | ND | ND | |
HCoV-OC43 | 34 | 33 | 25 | 42 | ND | ND | |
HCoV-HKU1 |
34 |
32 |
25 |
40 |
ND |
ND |
|
Alphacoronavirus | HCoV-229E | 28 | 30 | 24 | 35 | ND | ND |
HCoV-NL63 | 29 | 28 | 21 | 36 | ND | ND |
*SARS-CoV-2, HCoV-OC43, MERS-CoV, HCoV-HKU1, HCoV-NL63, SARS-CoV, HCoV-229E (GenBank accession nos. NC_045512.2, NC_006213.1, NC_019843.3, NC_006577.2, NC_005831.2, NC_004718.3, and NC_002645.1). Protein sequences were aligned by using ClustalW (https://www.genome.jp/tools-bin/clustalw). RBD, receptor-binding domain; ND, not done; S, spike; S1, N-terminal subunit of the spike protein; S2, C-terminal subunit of the spike protein; S1A, domain A of the spike S1 subunit; SARS-CoV, severe acute respiratory syndrome coronavirus; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
1These authors contributed equally to this article.
Page created: April 08, 2020
Page updated: June 18, 2020
Page reviewed: June 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.